Introduction CD4 þ CD25 þ Foxp3 þ T
regulatory cells (Tregs) mediate
immune suppression to control unfavorable immune responses against self-antigens or pathogens (1, 2) . Tregs are found in high numbers in tumors of different tissue origin, and their presence correlates with poor antitumor immune response and poor prognosis (3) (4) (5) (6) . In melanomas, it has been reported that 25% of the CD4 þ T cells found in tumors are Foxp3 þ , with only about 7% found in the peripheral blood of the same patients (7, 8) .
These results indicate that melanomas attract and retain Tregs in the tumor, or that tumor-infiltrating Tregs can expand in the tumor microenvironment. In addition, it has been reported that the tumor microenvironment can generate inducible Tregs from CD4 þ CD25 À T cells (9, 10) , with the total pool of Tregs being composed, therefore, of both natural Tregs and newly arising induced peripheral Tregs (10) (11) (12) . Tregs, like other T cells, respond to T-cell receptor (TCR) stimulation and can be induced to expand with cytokines such as IL-2 (13, 14) . Upon activation, Tregs also express costimulatory receptors, such as inducible T-cell costimulator (ICOS) and CD28, that further boosts their activation, proliferation, and survival (15) . ICOS costimulation of CD4 þ T cells has been found to facilitate the production of Th2 cytokines such as IL-4, IL-13, and IL-10 (16) . Recently, a number of normal tissues have been reported to express ICOS-L and regulate CD4 þ T-cell activation and cytokine production (17) (18) (19) (20) (21) (22) (23) (24) . In several mouse models of autoimmunity, the CD4 þ CD25 þ Tregs expressing ICOS were shown to produce IL-10 and control autoreactive T cells in the invaded organs such as the prediabetic pancreas (25, 26) . Tregs present in melanoma have also been found to express ICOS on their surface (27) , and ICOS þ Tregs have been shown to potently inhibit T-cell responses indirectly through suppressing antigen-presenting cells with 27) . In cancer, the source of ICOS costimulation for Tregs is largely unknown. Although DC, pDC, and B cells can express ICOS-L (16), there are no reports that ICOS-L expressed by tumor cells can regulate CD4 þ T-cell activation, and the expression of ICOS-L in melanoma has not been characterized yet.
In this work, we report that both cultured and freshly isolated metastatic melanoma cells from stage IV melanoma patients express ICOS-L on their surface and can costimulate Tregs to promote high expression of CD25, Foxp3, and ICOS.
Materials and Methods

Cell lines
L cells transfected with CD32 and ICOS-L were a gift of Yong-Jun Liu. Melanoma tumor cell lines used in the study: WM35, WM35P1N1, WM35P2N1, A684, 888, 938, 624, WM793, WM793P1N1, WM793P2N1, A375, A375S2, 526, 2088, 2089, 2084, A681, A682, A687, 1007, MEMO, and SK-MEL-1.
Antibodies
ICOS-L, B7-H1, ICOS, CD86, Foxp3, rat IgG, and hamster IgG isotypes antibodies were from eBioscience. Human leukocyte antigen (HLA) class II, CD4, CD25, CD45RA, CD45, CD8, CD16, IL-10, and IFN-g antibodies were from BD Biosciences. Anti-MCSP-1 (melanoma-associated chondroitin sulfate proteoglycan-1) was from Miltenyi Biotec. Cytokine analysis by intra- Screening of melanoma cell lines and primary melanomas for B7 molecule expression by flow cytometry Melanoma cell lines were harvested with protease-free dissociation buffer (Invitrogen). Metastatic melanoma tissue was obtained by surgical resection with patient informed consent using clinical and laboratory protocols approved by the M. D. Anderson Cancer Center Institutional Review Board (see Table 1 ). Tumor samples were processed within 2 hours of resection first by cutting them into 5-8 mm 2 pieces followed by mechanical disruption using a Seeward Stomacher (Fisher). The cell suspensions were applied over a 70% Ficoll-Isopaque layer in Dulbecco's phosphate buffer saline. Tumor cells were collected from the gradient interface, washed and stain with antibodies against MCSP1, HLA class II, CD45, and either ICOS-L, B7-H1, or CD86. Before flow cytometry analysis, 7-amino-actinomycin D (7-AAD) was added to the cells. All samples were analyzed using a BD FACScanto II flow cytometer using FACSDiva 5.1 software (BD Biosciences).
T-cell activation and staining of isolated T cells after coculture with melanoma cells
Melanoma cell lines and L cells were irradiated with 200 and 70 Gy, respectively, before plating. CD4 þ T cells from peripheral blood mononuclear cells (PBMC) were purified using Miltenyi microbeads and further sorted into CD4 þ and CD25 À and
. Cells were cultured together with irradiated melanoma or L cell lines and soluble anti-CD3 IgE (CLB-T3/ 4.E) at 20 ng/mL, or 100 ng/mL OKT-3. IL-2 (20 U/mL final) was added to all cultures. Where indicated, sorted cells were labeled with 1 mM carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) (Invitrogen). Five to six days later, the cells were analyzed for the expression of CD4, ICOS, CD25, and Foxp3. SB431542, a TGF-b-R1 kinase inhibitor, was used at 5 mM (Sigma-Aldrich). IL-10 and IFN-g production was evaluated after activating the cultured cells for 6 hours with PMAþIonomycin. Brefeldin A (Golgi-Stop; BD Biosciences) was added during the last hour of incubation. Cytokine staining was done using BD Fix/Perm reagents (BD Biosciences).
Blockade of ICOS-L in a tumor mouse model C57BL/6 mice were injected intravenously (i.v.) with 10 5 B16-OVA cells (day 0) followed by intraperitoneal (i.p.) transfer of 2 million CD4 þ OT-II-Ly5.2 T cells on day 2. Starting on day 2, the mice were treated with 100 mg of anti-ICOSL antibody (28) , or rat IgG, and thereafter for every 2 days until the end of the experiment on day 17. On day 17 after tumor challenge, Foxp3, CD25, CD4, and ICOS expression on T cells from lung tissues were evaluated by flow cytometry (29) . C57BL/6 mice were purchased from the NCI and OT-II CD45.1 mice were from our colony.
T-cell suppression assay
For the T-cell suppression assays, the isolated Tregs from the cocultures were washed and rested in culture medium with no IL-2 for 1 day. Autologous-sorted CD4 þ CD25 À cells labeled with CFDA-SE were cultured at a 1:1 ratio with the isolated and rested Tregs. An equal number of autologousirradiated PBMC pulsed with 10 ng/mL of anti-CD3 were added, and the cultures incubated for 6 days. Cell division was analyzed by flow cytometry measuring CFDA-SE dilution. 
Results
ICOS-L is expressed by human melanoma cells
While searching for the expression of B7 molecules in mouse tumors, we found that ICOS-L (also known as B7H, B7RP-1, GL50, or B7-H2) was expressed by the B16/F10 melanoma excised from C57BL/6 mice (Fig. S1 ). Then we checked whether human melanoma cells also express ICOS-L. We first analyzed mRNA expression of ICOSL on a panel of human melanoma cell lines and found that some had high ICOS-L mRNA expression (Fig. 1A ) when compared with wildtype L cells. As a positive control, we used L cells stably transduced with human ICOS-L (Fig. 1A, bottom) . The cell surface expression of ICOS-L was found in some melanoma cell lines, which correlated to the mRNA levels of expression ( Fig. 1B) and after the analysis of 22 melanoma cells lines we found that about 45% of the cells lines expressed ICOS-L (see Supplementary Table 1 ). Some cells expressed high levels of ICOS-L such as WM35 and some only a discrete or low expression such as 938. Normal melanocytes showed low levels of ICOS-L mRNA and negative ICOS-L cell surface protein expression (data not shown). Thus, a significant number of human melanoma cell lines can express ICOS-L protein on the cell surface.
B7 molecule expression on antigen-presenting cells (APC) and other tissues is regulated by cytokines. For example, IFN-g has been shown to increase B7-H1 expression in both APC and tissues (30) . We then tested the influence of IFN-g on ICOS-L expression by melanoma lines. Although, B7-H1 mRNA expression was increased by IFN-g, ICOS-L mRNA expression was not influenced by IFN-g in a number of melanoma cell lines (Fig. S2A ). The ICOSL expression was confirmed by FACS staining where an increase in cell surface B7-H1 was found after IFN-g pretreatment, with only a slight or no induction of cell surface ICOS-L expression (Fig. S2B) . We also tested other cytokines, such as TNF-a, IL-1b, and IL-6 and did not find any change in the ICOS-L expression (data not shown). Therefore, ICOS-L expression by melanoma cells is not influenced by IFNg and these other inflammatory cytokines.
The expression of ICOS-L in melanoma cell lines could appear as a result of a long-term culture-inducing somatic variation. Therefore, we screened fresh melanoma tumors for the expression of ICOS-L immediately after surgical excision from stage IV melanoma patients. The tumors were obtained from different locations in the body and represented both nonlymph node-derived as well as lymph node-derived metastases (Table 1) . After processing the tumors, a cell suspension enriched for melanoma cells was analyzed by FACS. After dead cell exclusion with 7-AAD, and exclusion of CD45 þ leukocytes, melanoma cells were selected with the specific marker MCSP-1 for analysis of ICOS-L expression (see Fig. S3 for the gating strategy). Here, we also found that about 25% of the fresh human melanomas were negative for ICOS-L ( Fig. 2A ), another 25% expressed low level of ICOS-L (Fig. 2B ), whereas about 50% of metastases had relatively high levels of cell surface ICOS-L expression (Fig. 2C) . A summary of the results of cell surface staining for ICOS-L on the 12 metastatic melanoma samples are shown in Fig. 2D . Therefore, human melanoma cells in vivo express ICOS-L and its expression is not simply induced by culture conditions. In addition, we have also cultured isolated tumor cells from patient material for up to 5 passages and confirmed the stable expression of ICOS-L in these new lines (data not shown). In addition to determining ICOS-L expression, we also analyzed B7-H1 and HLA class II on these freshly isolated metastases ( Fig. 2A-C ) and found that a number of tumors coexpressed ICOS-L and B7-H1 as well as HLA class II. As summarized in Table 1 , 50% of freshly isolated melanoma samples expressed high levels of HLA class II with differential coexpression of ICOS-L, B7-H1, or both ICOS-L and B7-H1. This result indicates that tumor cells may be able to provide direct antigenic stimulation in context with ICOS costimulation.
ICOS-L signaling delivered by melanoma cells promote sustained CD25 and Foxp3 expression by Tregs
We next designed a series of experiments to test whether ICOS-L-expressing melanoma cells could provide costimulation to purified CD4 þ T cell populations. We sorted (Fig. 3A  right panels) . We tested several normal donors Treg in our cocultures with melanoma lines and found that in every case there was an induction of Foxp3 hi cells when the T regs were cultured with ICOS-L expressing melanoma lines (Fig. 3B) . Therefore, we concluded that ICOS-L costimulation during the activation of T regs positively induces the expression of Foxp3 and ICOS.
To confirm the Foxp3 induction by ICOS-L costimulation driven by melanoma lines, we generated melanoma cell lines that could express ICOS-L and human CD32 (Fc receptor) on their surface, such that the CD3 complex could be cross-linked on the T cells by OKT3 after CD32 binding with or without ICOS-L costimulation (Fig. S4A) . WM793, which does not (Fig. S4B, left panels) and that the Foxp3hi cells from these cultures had more than 80% ICOS þ cells (Fig. S4B, right (Fig. 3C, middle panel) . These results indicated that ICOS-L costimulation of Tregs slows the cell division rate and sustains Foxp3 hi expression. Since TGF-b has been found to induce Foxp3 expression in non-Tregs, we then investigated the role of TGF-b signaling in our cocultures. For this, we used the TGF-b signaling inhibitor SB431542 (34) during the activation of CD25 þ T cells with the ICOS-L þ melanoma cells. We found that the addition of SB431542 did not affect the cell division rate or the Foxp3 expression of the CD25 þ T cells (Fig. 3C, right panel) . Thus, the enhanced Next we asked whether patients with melanoma would have a CD25
þ T cell population in the tumor environment. We isolated tumor-infiltrating lymphocytes (TIL) and PBMC from stage IV melanoma patients and analyzed T cell populations. We found that melanoma patients have 10 times
cells in the TIL when compared
with PBMC, and they also have increased numbers of these cells expressing ICOS (Fig. 3D ). This suggests that the tumor environment indeed favors
Blockade of ICOS-L reduces the generation of CD4
To confirm that Foxp3 induction in Treg cells is driven by ICOS-L stimuli, we sorted CD4
þ CD25 þ T cells, labeled them with CFDA-SE and activated them with the tumors, as previously, but this time we added anti-ICOSL blocking antibody or mouse IgG. For these experiments, we used both normal donors and PBMC from stage IV melanoma patients. We found that blockade of ICOS-L reduced the generation of Foxp3 hi CFDA-SE low cells in normal donors by about 55% when the cells were cultured with ICOSL þ melanomas but did not alter the percentage of cells generated by ICOSL À melanomas ( Fig. 4A and B) . Similar level of cell division and Foxp3 induction were found in cells from melanoma patients. These results indicate that a part of the Foxp3 hi Treg cells generated by activation with the tumors expressing ICOS-L is dependent on ICOS-L costimulation.
To further confirm that ICOS-L expressed by the tumor is involved in the appearance of 
Discussion
Costimulatory molecules of the B7 family control the activation of T cells during antigen recognition on APC and other tissues. In cancer, some of these B7 molecules can be immune suppressive and facilitate immune evasion. For example, the expression of B7-H1 in tumors, the ligand for PD1, inhibits the expansion and survival of antitumor T cells and is associated with worse prognosis (30, 35) . The results presented in this paper demonstrate that in addition to B7-H1, a high proportion of human metastatic melanomas, as well as B16, a wellknown murine melanoma, also express cell surface ICOS-L (B7H). It still remains unknown how ICOS-L expression is regulated in melanomas or normal melanocytes. We did not find ICOS-L induced expression in melanomas by a number of proinflammatory cytokines (e.g., IL-6, IL-1b, TNF-a, IFN-g) A B Figure 5 . 
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